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RNA interferenceEstradiol (E2) regulates several cellular functions through the interaction with estrogen receptor subtypes,
ERα and ERβ, which present different functional and regulation properties. ER subtypes have been identiﬁed
in human astrocytomas, the most common and aggressive primary brain tumors. We studied the role of ER
subtypes in cell growth of two human astrocytoma cell lines derived from tumors of different evolution
grades: U373 and D54 (grades III and IV, respectively). E2 signiﬁcantly increased the number of cells in
both lines and the co-administration with an ER antagonist (ICI 182, 780) signiﬁcantly blocked E2 effects.
ERα was the predominant subtype in both cell lines. E2 and ICI 182, 780 down-regulated ERα expression.
The number of U373 and D54 cells signiﬁcantly increased after PPT (ERα agonist) treatment but not after
DPN (ERβ agonist) one. To determine the role of SRC-1 and SRC-3 coactivators in ERα induced cell growth,
we silenced them with RNA interference. Coactivator silencing blocked the increase in cell number induced
by PPT. The content of proteins involved in proliferation and metastasis was also determined after PPT treat-
ment. Western blot analysis showed that in U373 cells the content of PR isoforms (PR-A and PR-B), EGFR,
VEGF and cyclin D1 increased after PPT treatment while in D54 cells only the content of EGFR was increased.
Our results demonstrate that E2 induces cell growth of human astrocytoma cell lines through ERα and its in-
teraction with SRC-1 and SRC-3 and also suggest differential roles of ERα on cell growth depending on astro-
cytoma grade.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Astrocytomas are the most common primary intracerebral neo-
plasms in humans, mainly found in adults between 30 and 50 years.
They are classiﬁed according to their histological characteristics in
four groups (I–IV), and the survival of patients is inversely related
to the tumor grade [1]. It is well known that the incidence of astrocy-
tomas is higher in men than in women (3:2); however, the role of sex
hormones in the development of these neoplasms has been poorly
investigated [2–4].
Estradiol (E2) is involved in the regulation of several physiological
and pathological processes in the brain and may play a role in the
control of brain tumor growth [5,6]. This hormone modulates several
functions through the interaction with its intracellular receptors
which are ligand-activated transcription factors that regulate theisclose.
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rights reserved.expression of several genes involved in reproduction, development,
metabolism and cell proliferation. There are two main intracellular
estrogen receptor (ER) subtypes named ERα and ERβ encoded by dif-
ferent genes with distinct functions and regulation [7–9].
ER expression is also differentially regulated by E2 in several cells
and tissues. In several cell types ERβ is up-regulated whereas ERα is
down-regulated by this steroid [10,11]. ERα down-regulation occurs
through a mechanism known as ligand-dependent proteolysis in
which E2 induces receptor phosphorylation, a signal for degradation
by the ubiquitin–proteasome pathway [12,13].
The transcriptional activity of ER has been linked to the interaction
with coactivators which are recruited by the activated steroid receptors
to target gene promoters [14–17]. The steroid receptor coactivator fam-
ily (SRC) consists of three members: SRC-1 (NcoA-1), SRC-2 (GRIP-1/
NcoA-2/TIF-2), and SRC-3 (AIB1/ACTR/pCIP/RAC3/TRAM-1) [14,18].
SRCs are expressed in several tissues including brain, where a dif-
ferential expression and regional distribution have been observed
[19]. SRC-1 is involved in rodent neuronal development, brain sexual
differentiation [20], and is required for the display of female sexual
behavior [21]. SRC-1 enhances ER transcriptional activity and inter-
acts with ligand-bound ER subtypes depending on the rat brain
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of several human cancer cell lines [23–25]. SRC-2 has been detected
in several rodent brain regions known to mediate a variety of
steroid-dependent functions [26–28]. This coactivator interacts with
ligand bound ERα, but not ERβ, in rat hippocampus and hypothala-
mus [29]. In most mice brain structures where SRC-1 is expressed,
SRC-2 is present at low levels, and the disruption of SRC-1 gene re-
sults in an up-regulation of SRC-2 expression [27]. Besides, SRC-2 to-
gether with SRC-1 has been localized in the nucleus of rat astrocytes
[30]. SRC-3 is expressed at high concentrations in the rodent hippo-
campus and it is mainly localized in the cytoplasm of rat astrocytes
[19,30,31]. This coactivator is frequently ampliﬁed and overexpressed
in several cancers such as those of breast, ovary, endometrium,
stomach, prostate, pancreas and esophagus [18,32–35]. Our group
has detected SRC-1 and SRC-3 expression by RT-PCR and Western
blot in U373 and D54 human astrocytoma cell lines [36], but their
role in brain tumors is unknown.
ER subtypes have been detected in several human brain tumors
such as astrocytomas, meningiomas, chordomas and craniopharyn-
giomas [2,37–40]. In astrocytomas, an inverse relation between the
content of ER and the tumor grade has been reported [2,37,41]. ERα
and ERβ are expressed in astrocytes and in astrocytomas but their ex-
pression is reduced in biopsies of high-grade human astrocytomas
[42] however, the function, regulation, and mechanisms of action of
ER subtypes in human astrocytoma cells are not known. Therefore,
we studied the role of E2 and its receptors in cell proliferation of
U373 and D54 human astrocytoma cell lines (derived from tumors
grades III and IV, respectively), the participation of SRC-1 and SRC-3
coactivators in E2 effects, as well as the regulation of ERα expression
by E2, and its antagonist ICI 182, 780.
2. Materials and methods
2.1. Cell culture
U373-MG and D54 human astrocytoma cell lines derived from
human astrocytoma grades III (ATCC, Manassas, VA) and IV (gener-
ously obtained by Dr. Andres Gutiérrez from Dr. Sontheimer laborato-
ry (Bringham, AL)) respectively, were used. Cells were grown in
10 cm dishes and maintained in Dulbecco's modiﬁcation of Eagle's
medium (DMEM), supplemented with 10% fetal bovine serum,
1 mM pyruvate, 2 mM glutamine, 0.1 mM non-essential amino acids
(GIBCO, NY) at 37 °C under a 95% air, 5% CO2 atmosphere.
2.2. Cell number and treatments
5×103 U373 or D54 cells were grown on 48-well plates and main-
tained as indicated in Cell culture section. 24 h before treatments,
mediumwas changed by DMEM phenol red free medium supplemen-
ted with 10% fetal bovine serum without steroid hormones (Hyclone,
Utah), 1 mM pyruvate, 2 mM glutamine, 0.1 mM non-essential amino
acids (GIBCO, NY) at 37 °C under a 95% air, 5% CO2 atmosphere. The
following treatments were applied at day 0: (1) vehicle (0.02% cyclo-
dextrin in sterile water); (2) 17-β estradiol (E2) (10 nM); (3) ICI 182,
780 (2 μM, ER antagonist); (4) E2+ICI 182, 780; (5) PPT (1 nM, it
displays a 410-fold selectivity for ERα compared to ERβ); (6) DPN
(1 nM, it displays a 70-fold selectivity for ERβ over ERα). The concen-
trations used for E2 and ICI 182, 780 have been previously reported
by our work group [36,43]. The concentration of PPT and DPN
(1 nM) used in the experiments was according to that used by other
authors [44–46]. Each experiment was performed in four indepen-
dent cultures. Cyclodextrin and E2 were purchased from Sigma-Al-
drich (St. Louis, MO). ICI 182, 780, PPT and DPN were from Tocris
Cookson Inc. (Ellisville, MO). Cells were harvested from incubation
every day during 6 consecutive days with PBS 1×+EDTA (1 mM).
The number of living cells, evaluated by a blind observer, wasmeasured by trypan blue dye exclusion using an inverted microscope
(Olympus CKX41, Center Valley, PA).
2.3. Protein extraction and Western blotting
5×105 cells were grown in 10 cm dishes and maintained as it has
been described in Cell culture section. 24 h before treatments, medi-
um was changed by DMEM phenol red free medium at 37 °C under
a 95% air, 5% CO2 atmosphere. ER agonists and ICI 182, 780 treatments
were applied for 24 h. Each experiment was performed in four inde-
pendent cultures. After all treatments cells were homogenized in
RIPA lysis buffer with protease inhibitors (1 mM EDTA, 2 μg/ml leu-
peptin, 2 μg/ml aprotinin, 1 mM PMSF). Proteins were obtained by
centrifugation at 20,000×g, at 4 °C for 15 min, and quantiﬁed by the
method of Bradford (Bio-Rad Laboratories, Hercules, CA). Proteins
(70 μg) were separated by electrophoresis on 8% SDS-PAGE at
20 mA. Colored markers (Bio Rad, CA, USA) were included for size de-
termination. Gels were transferred to nitrocellulose membranes for
2 h (Amersham, NJ, USA) (60 mA, at room temperature in semi dry
conditions), which were blocked at room temperature with 3% non-
fat dry milk and 1% bovine serum albumin for 2 h. Membranes were
then incubated with 0.8 μg/ml of antibodies against ERα (Santa Cruz
sc-8002, CA, USA), ERβ (Santa Cruz sc-6821), SRC-1 (Millipore
05–522, MA, USA), SRC-3 (Millipore 05–490), EGFR (Santa Cruz sc-
003), VEGF (Santa Cruz sc-152), cyclin D1 (Santa Cruz sc-A12) or
3 μg/ml of mouse anti-PR monoclonal antibody (CRM 302C Biocare
Medical, CA, USA), which recognizes both PR isoforms (PR-A and
PR-B), at 4 °C overnight. Blots were then incubated with 400 μg/ml
of secondary antibody conjugated to horseradish peroxidase (Santa
Cruz Biotechnology, Santa Cruz, CA) for 45 min.
In order to correct differences in the amount of total protein loaded
in each lane, ERα, ERβ, SRC-1, SRC-3, PR isoforms, VEGF, EGFR and cylcin
D1 protein content were normalized to that of α-tubulin. Blots were
stripped with glycine (0.1 M, pH 2.5, 0.5% SDS) at 4 °C overnight and
at room temperature for 30 min, and reprobed with a 1:10,000 dilution
mouse anti-α-tubulin monoclonal antibody (Sigma T9026, St. Louis,
MO) at room temperature for 2 h. Blots were incubated with a 1:3000
dilution goat anti-mouse IgG conjugated to horseradish peroxidase
(Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h at room temperature.
Signals were detected by enhanced chemiluminescence (ECL) (Amer-
sham, NJ) with a constant exposure time of 1 min for ERα, ERβ, SRC-1,
SRC-3, VEGF, EGFR and cylcin D1, 5 min for PR and 20 s for α-tubulin.
The antigen–antibody complex was detected as the area under a peak
corresponding to a band density (the area is given in inches, as the de-
fault scale is 72 pixels/in.) in a semiquantitative way using HP Scanjet
G3110 apparatus (Hewlett-Packard Development Company, USA) and
the Scion Image software (Scion Corp., MD, USA). In order to minimize
inter-assay variations, all Western blots were carried out in parallel.
2.4. Cell transfection
Four different RNA interferences were purchased from Santa Cruz
Biotechnology (CA, USA): one short hairpin RNA (shRNA) targeting
coactivator SRC-1, one small interfering RNA (siRNA) targeting coac-
tivator SRC-3 and two control RNAs, shRNA and siRNA, respectively.
Both control RNA interferences have a scramble sequence that does
not lead to the speciﬁc degradation of any known cellular mRNA.
U373 and D54 cells were transferred to six-well plates. Cells grown
to a conﬂuence of 60% were transfected with 1 μg of RNA interference
using FUGENE® HD Transfection Reagent (Roche, Basel, Switzerland)
as described by the manufacturer's instruction.
2.5. ER subtypes and coactivators mRNA expression
Total RNA was isolated from U373 and D54 cells with the single-
step method based on guanidine isothiocyanate/phenol/chloroform
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RNA concentrationwas determined by absorbance at 260 nmand its in-
tegrity was veriﬁed by electrophoresis on 1% denaturing agarose gels in
the presence of 2.2 M formaldehyde. The ﬁrst strand cDNAwas synthe-
sized from 5 μg of total RNA by using M-MLV reverse transcriptase and
oligo dT18 primers according to its protocol (Invitrogen, CA). 10 μl of RT
reactionwas subjected to PCR in order to simultaneously amplify a gene
fragment of ERα, ERβ or SRC-1, SRC-2, SRC-3 and 18S ribosomal RNA,
the latter was used as an internal control. The sequences of the speciﬁc
primers for ERα ampliﬁcation fragment (from+1760 to+1912) were
5′-[AGC ACC CTG AAG TCT CTG GA]-3′ for the forward primer (F) and
5′-[GAT GTG GGA GAG GAT GAG GA]-3′ for the reverse primer (R), for
ERβ ampliﬁcation region (from +1683 to +1855) were 5′-[AAG AAG
ATT CCC GGC TTT GT]-3′ (F) and 5′-[TCT ACG CAT TTC CCC TCA TC]-3′
(R). The sequences of the speciﬁc primers for SRC-1 ampliﬁcation frag-
ment (from +1015 to +1333) were 5′-[CCTCCAGCTATTACGGGTG-
TAG]-3′ (F) and 5′-[ATGATGAAAGGTTGCATGTCTG]-3′ (R), for SRC-2
(from +1186 to +1505) were 5′-CTGATGGCACTCTTGTTGCT-3′ (F)
and 5′-TTCATTCCCCCAGAACCAC-3′ (R) for SRC-3 ampliﬁcation region
(from +2103 to +2440) were 5′-[GTCATTCCTCCTTGACCAACTC]-3′
(F) and 5′-[ATCCCTGTCCAGCAGGTATCTA]-3′ (R). The 50 μl PCR reac-
tion included: 10 μl of previously synthesized cDNA, 20 mM Tris–HCl
(pH 8.3), 50 mM KCl, 1 mM MgCl2, 0.2 mM of each dNTP, 0.5 μM of
each primer, and 2.5 units of Taq DNA polymerase. Negative controls
without RNA and with non-retrotranscribed RNA were included in all
the experiments. After an initial denaturation step at 95 °C for 5 min,
PCR reaction was performed for 30 cycles. The cycle proﬁle for ER
subtypes and 18S genes ampliﬁcation was: 30 cycles at 95 °C, 1 min;Fig. 1. Effects of E2 and ICI 182, 780 on the cell number of U373 and D54 human astro-
cytoma cell lines. U373 (Upper panel) and D54 (Lower panel) cell lines were treated
with vehicle (V) (0.02% cyclodextrin), E2 (10 nM), the ER antagonist ICI 182, 780
(2 μM), and E2 plus ICI 182, 780 during a six day time course. Every day cells were har-
vested and cell number was determined by trypan blue dye exclusion using an inverted
microscope. Data are mean±S.E.M. n=4; *Pb0.05 vs. all groups, **Pb0.05 vs. V.60 °C (58 °C for SRCs), 1 min; and 72 °C, 1 min. A ﬁnal extension cycle
was performed at 72 °C for 5 min. All PCR productswere always studied
and analyzed together throughout the experiments. PCR products were
separated on 2% agarose gels and stained with ethidium bromide. The
image was captured under a UV transilluminator. The intensity of
ERα, ERβ or 18S bands was quantiﬁed by densitometry using the
Scion Image software (Scion Corp., Maryland). ER subtypes expression
level was normalized to that of 18S.
2.6. Statistical analysis
All data were analyzed and plotted utilizing GraphPad Prism ver-
sion 4.00 for Windows software (GraphPad Software, San Diego,
CA). Satistical analysis between comparable groups was performed
using ANOVA with Bonferroni's post-test. A value of pb0.05 was con-
sidered statistically signiﬁcant as stated in the ﬁgure legends.
3. Results
3.1. Effects of E2 and ICI 182, 780 on the growth of U373 and D54 human
astrocytoma cell lines
To study the effect of E2 on cell growth of U373 and D54 astrocy-
toma cell lines, a time-course study over a 6-day period was per-
formed. In U373 cells E2 treatment signiﬁcantly increased the
number of cells on the fourth day of culture and in D54 cells on theFig. 2. Effects of ERα agonist PPT and ERβ agonist DPN on cell number of U373 and D54
human astrocytoma cell lines. U373 (Upper panel) and D54 (Lower panel) cell lines
were treated with V (0.02% cyclodextrin), E2 (10 nM), PPT (1 nM) and DPN (1 nM)
to determine cell number during a six day time course. Every day cells were harvested
and cell number was determined by trypan blue dye exclusion using an inverted mi-
croscope. Data are mean±S.E.M. n=4. Data were analyzed by ANOVA, for D54
F=18.74, pb0.001; for U373 F=5.88, pb0.001.*Pb0.05 vs. all groups, **Pb0.05 vs. V.
382 A. González-Arenas et al. / Biochimica et Biophysica Acta 1823 (2012) 379–386ﬁfth day. In both cell lines the E2 effect persisted until day 6 (Fig. 1).
Treatment with ICI 182, 780 did not signiﬁcantly change the number
of U373 and D54 cells as compared with vehicle. ICI 182–780 co-
administered with E2 signiﬁcantly blocked the effects of this hor-
mone on days 4 and 5, and compared with vehicle in U373 and D54
cells, respectively (Fig. 1). These data suggest that E2 increases cell
number through the interaction with ER subtypes.
3.2. Effects of ER stimulation on the growth of U373 and D54 cells
In order to ﬁnd out which ER subtype is involved in cell growth,
we used ER speciﬁc agonists: PPT for ERα and DPN for ERβ. A time-
course study over a 6-day period with PPT (1 nM) or DPN (1 nM),
was performed in U373 and D54 human astrocytoma cell lines. PPT
treatment signiﬁcantly increased the number of cells in a similar
manner to that observed with E2. In both cell lines the PPT effect per-
sisted until day 6 (Fig. 2). The treatment with DPN did not signiﬁcant-
ly change the number of U373 and D54 cells as compared with
vehicle (Fig. 2). These results demonstrate that ERα is the subtype
implicated in the increase of cell number mediated by E2.
3.3. Expression and regulation of ERα in U373 and D54 cell lines
ER subtype expression was determined by RT-PCR in U373 and
D54 cell lines. Fig. 3 shows that ERα content was higher than that of
ERβ in both cell lines, however, ERα expression was lower in D54
cells as compared to U373 cells (ERα:ERβ ratio 3:1 in U373 andFig. 3. Expression and regulation of ERα in U373 and D54 cell lines. U373 and D54 cells wer
(Upper panel). ERα and ERβ expression was determined by RT-PCR and the 18S ribosomal R
trophoresis (left), and the statistical analysis (right) of the ER-α/ER-β expression ratio for b
analysis (Lower panel) was performed to determine ER-α content in U373 (left) and D54 (ri
and E2 plus ICI 182, 780. Representative blot images for ERα content and control protein tu1.5:1 in D54) (Fig. 3). We studied the effects of E2 and ICI 182, 780
on the content of ERα in astrocytoma cell lines. We detected a
66 kDa double band corresponding to ERα. E2 treatment down-
regulated ERα content as compared with vehicle in U373 cells, and
by contrast E2 did not regulate this receptor in D54 cells. ICI 182,
780 down-regulated ERα in both cell lines. E2 plus ICI 182, 780 did
not have a synergistic effect over ERα down-regulation in astrocyto-
ma cell lines (Fig. 3). These results suggest that differences in ERα ex-
pression and regulation by E2 between both cell lines could be related
to the evolution grade of the tumors they derive from. We also
detected ERβ as a 55 kDa band (Supplementary Fig. 1), in contrast
to the effect observed in ERα, E2 and ICI 182, 780 treatments in-
creased ERβ protein content.3.4. Role of SRC-1 and SRC-3 coactivators on the growth of astrocytoma
cell lines mediated by ERα activation
The transcriptional activity of ERα has been linked to its interac-
tion with general classes of coactivators such as SRC-1, SRC-2, and
SRC-3. These coactivators must be coexpressed with steroid receptors
in the same cell to mediate the effects of the latter. We found that
both cell lines highly expressed SRC-1 and SRC-3. In contrast, the ex-
pression of SRC-2 was very low (Supplementary Fig. 2). Therefore, we
decided to only evaluate the participation of SRC-1 and SRC-3 in the
growth of astrocytoma cell lines dependent on ERα activation. SRC-
1 or SRC-3 was silenced with RNA interference in U373 and D54
cells treated with PPT. Coactivator silencing blocked PPT increase ine lysed and RNA was extracted by a guanidine isothiocyanate/phenol/chloroform assay
NA gene was used as a loading control. Representative image of a 2% agarose gel elec-
oth cell lines are shown. Data are mean±S.E.M. n=4; *Pb0.05 vs. U373. Western blot
ght) cells after treatment with V (0.02% cyclodextrin), E2 (10 nM), ICI 182, 780 (2 μM),
bulin in U373 and D54 are shown. Data are mean±S.E.M. n=4; *Pb0.05 vs. V.
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coactivator content was determined on day 3 after PPT treatment
(Fig. 4). The coactivator silencing was maintained until the sixth day
of culture after transfection with RNA interference (Supplemental
Fig. 3). In summary, our results suggest that E2 effect on cell growth
of U373 and D54 cells depends on ERα activation and its interaction
with SRC-1 and SRC-3 coactivators.
3.5. Regulation of PR isoforms, cyclin D1, EGFR and VEGF expression by
ERα
Progesterone receptor isoforms (PR-A and PR-B), cyclin D1, VEGF
and EGFR [47–49] are involved in metastasis and proliferation of
different kinds of tumors such as gliomas. These genes are induced
by E2 in cell lines derived from human breast and endometrial tumors
[50–52]. Increase in astrocytoma cell number depends on ERα activa-
tion; therefore, we studied whether the content of these proteins was
regulated by ERα activation in human astrocytoma cell lines. The con-
tent of PR isoforms, cyclin D1, EGFR and VEGF was assessed in U373
and D54 cell lines after PPT treatment. Western blot analysis showed
that in U373 cells the content of both PR isoforms, cyclin D1, EGFR
and VEGF was increased after PPT treatment (Fig. 5) whereas in
D54 cells only the content of EGFR was increased after PPT treatment
(Fig. 5). Thus, the expression of proteins involved in tumor progres-
sion was regulated by ERα depending on the tumor evolution grade
from which the cell lines were derived.
4. Discussion
In the present study, we examined the role of E2 and its intracel-
lular receptors (ERα and ERβ) in the regulation of cell growth of
two human astrocytoma cell lines: U373 and D54 (derived from tu-
mors of grades III and IV, respectively). The results show that E2 in-
creases cell growth in both cell lines, and the ER antagonist ICI 182,
780 blocked E2 effect. Interestingly, it has been observed that in C6
mouse glioma cells estrogen biosynthesis inhibition by melatonin de-
creased the growth of these cells [53]. Barone et al. [54] found that E2
decreased tumor growth in nude rats intracerebrally implanted with
U87 MG glioblastoma cell line; however, cell proliferation increased
at 72 h after 10 nM of 2-hydroxyestradiol treatment in in vitroFig. 4. Effect of SRC-1 and SRC-3 silencing on changes in cell number induced by PPT in U3
lines were transfected with SRC-1 shRNA, SRC-3 siRNA and control RNAs interference, and
number was determined as in Fig. 1. Representative Western blots of SRC-1 and SRC-3 from
(cells treated with transfection reagent without RNA interference). Data are mean±S.E.M.experiments. The invasiveness of glioma cells is mediated in part by
their interaction with the surrounding environment that involves as-
trocytes and extracellular matrix which synthesize many molecules
that inﬂuence cell proliferation. Differences between in vitro and
in vivo results could be due to the modulator effects of tumor micro-
environment on E2 actions.
E2 can exert its effects through genomic or non-genomic mecha-
nisms. Our results suggest that E2 effects on astrocytoma cell growth
occur via a classical genomic mechanism through its interaction with
ERα, since a speciﬁc agonist of this subtype (PPT) increased cell num-
ber whereas an ERβ agonist (DPN) did not exert any signiﬁcant effect.
ERα has been mainly detected in low-grade tumors and in several
cases its expression is reduced or lost during tumor development.
Nevertheless, it is possible that low levels of ERα have been unde-
tected mostly due to technical procedures such as immunohisto-
chemistry [42]. ERβ expression is known to decline in high-grade
tumors and to parallel the loss of differentiation [37]. We have
detected ERα and ERβ expression by Western blot in U373 and D54
cell lines in a previous work [36]. In this study the expression of
ERα and ERβ diminished in D54 cells compared to U373 cells. The
minor ERα expression in D54 cells makes the overall ERα/ERβ ratio
to be signiﬁcantly lower than in U373 cells. These ﬁndings correlate
with those observed in tumor biospsies where expression of ERs is re-
duced during tumor development [37,42]. The change in the ratio of
ER expression subtypes could be related to a differential regulation
of estrogen-dependent genes in cells derived form astrocytomas of
the highest evolution grade.
In cell-based studies, ERβ exhibits an inhibitory action on ERα-
mediated gene expression and in many cases, opposes the actions of
ERα [55]; in breast cancer ERα appears to play a predominant role
in cell proliferation, while ERβ is suggested to be antiproliferative
[56]. In this work we found that ERα down-regulation via E2 occurred
in U373 cells but not in D54 cells while in both cell lines ICI 182, 780
down-regulated ERα. It has been seen that E2 and ICI 182, 780 down-
regulate ERα in several cell lines such as MCF-7 breast cancer cells, in
which the protein half-life decreased [10,11,57]. Studies in MCF-7
cells have shown that the speciﬁc antagonist ICI 182, 780 induces
ERα degradation [58]. E2 mediated ERα degradation is dependent
on transcription, coactivator recruitment, receptor phosphorylation,
ubiquitination and degradation via 26S proteasome, whereas73 and D54 human astrocytoma cell lines. U373 (Left panel) and D54 (Right panel) cell
then treated with PPT (1 nM). Every day during six days cells were harvested and cell
cells lysed at day 3 after PPT treatment are shown in each panel. Mock: vehicle control
n=4. *Pb0.05 vs. Mock, Control shRNA and Control siRNA. **Pb0.05 vs. Mock.
Fig. 5. Effect of ERα agonist PPT on PR, cyclin D1, EGFR and VEGF content in U373 and D54 human astrocytoma cell lines. U373 and D54 cells were lysed after PPT (1 nM) treatment
and proteins (70 μg) were separated by electrophoresis on 8% SDS-PAGE gel. Proteins were transferred to nitrocellulose membranes and incubated with antibodies for PR, cyclin D1,
EGFR and VEGF. Protein antibody complexes were detected by ECL. A representative Western blot is shown (Upper panel). Statistical analysis for PR, cyclin D1, EGFR, or VEGF con-
tent relative to tubulin in U373 and D54 cell lines is shown (Lower panel). Data are mean±S.E.M. n=4; *Pb0.05 vs. V.
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clear matrix [11]. We observed that the number of U373 cells was
lower with E2+ICI 182, 780 treatment compared to vehicle (Fig. 1).
This could be related to a higher ERα degradation induced by the
agonist+antagonist treatment as it was observed in Fig. 3.
SRC-1 and SRC-3 interact with ER subtypes in a ligand-dependent
manner and enhance transcriptional activity of the ER via histone
acetylation and recruitment of additional coactivators [16]. In this
study, we determined that depletion of SRC-1 or SRC-3 decreased
proliferation of U373 and D54 cells mediated by ERα. The ability of
SRC-3 to contribute to cancer cell growth has been relatively well
characterized. It has been reported that the reduced proliferation of
SRC-3-depleted MCF-7 cells was due to their decreased progression
into the S and G2-M phases of the cell cycle as well as an increase in
the number of cells undergoing apoptosis [59]. Besides, SRC-3stimulates the expression of genes involved in DNA replication, and,
hence, cells lacking SRC-3 do not effectively enter into S phase [60].
The ability of SRC-1 to affect cell proliferation is less well studied.
An experiment conduced with MCF-7 cells stably overexpressing
SRC-1 indicated that this coactivator increased cell growth induced
by E2 [24,61].
The control shRNA SRC-1 itself rendered an effect on cell growth
compared to our Mock vehicle control (cells treated with transfection
reagent without RNA interference) in D54 cells. It is possible that this
cell line is more sensitive to the scramble sequence of the control
shRNA than the U373 cell line. shRNAs and siRNAs have the potential
to cause diverse and nonspeciﬁc effects when introduced into cells, in
addition to silencing speciﬁc target genes. One off-target effect is the
sequence-independent activation of the type I IFN pathway [62–64].
This pathway activation may have an effect on astrocytoma cell
385A. González-Arenas et al. / Biochimica et Biophysica Acta 1823 (2012) 379–386growth [65,66]. Although this effect could limit the interpretation of
our results, the difference between shRNA SRC-1 and control shRNA
is clear, and statistically different to let us state that silencing of
SRC-1 reduces cell growth in D54 cells. This effect of transfected con-
trol RNAs interference has been reported in other works [67,68].
Growth factors and their receptors, cell cycle control proteins and
steroid hormone receptors are associated with the biology of malig-
nant gliomas and other types of cancer. Changes in their expression
pattern may result in cell proliferation, metastasis and angiogenesis
[4,47,69–71]. Here we show that in U373 cells VEGF, EGFR, cyclin
D1 and PR isoforms increased its expression after PPT treatment
while in D54 only EGFR augmented its expression. The increase in
all these proteins content by PPT suggests that some of the effects
of E2 on cell proliferation and metastasis are mediated by changes
in the expression of PR isoforms, cyclin D1, VEGF and EGFR through
ERα. Differences in protein expression between astrocytoma cell
lines could be related to the tumor grade they derive from. A higher
evolution grade in tumors implies a more dedifferentiated and malig-
nant phenotype, which may correlate with the loss of gene expres-
sion regulation. Other proteins such as PDGF or CXCR4 that have
been reported to be necessary for glioma proliferation [72,73] should
be further studied in U373 and D54 astrocytoma cell lines.
We conclude that E2 induces cell growth in human astrocytoma
cell lines through the interaction with its intracellular receptor ERα,
the recruitment of SRC-1 and SRC-3 coactivators, and the regulation
of the expression of genes involved in cell cycle, angiogenesis and
metastasis. The importance of our study was to identify one pathway
through which estrogens can exert their effects on astrocytoma cell
lines. Nevertheless, its impact in patients with gliomas, and the
study on a glioblastoma in vivo model, awaits further work.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.bbamcr.2011.11.004.
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